ArticleThe Lancet. Oncology2018
Lung cancer's real adjuvant EGFR targeted therapy questions.
Article in The Lancet. Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.Nature communications · 2021Trial
- Targeted Therapy in Early Stage Non-small Cell Lung Cancer.Current treatment options in oncology · 2022Review
- Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIALung Cancer (Auckland, N.Z.) · 2022Article
- Elevation of EIF4G1 promotes non-small cell lung cancer progression by activating mTOR signalling.Journal of cellular and molecular medicine · 2021Article
- Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?Translational lung cancer research · 2020Article
- Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.Translational lung cancer research · 2019Article
- Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer.Translational lung cancer research · 2019Review
- SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.Annals of translational medicine · 2019Article
- Adjuvant TKIs: still an optimal choice.Journal of thoracic disease · 2018Article
- How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.Journal of thoracic disease · 2018Article
- Liquid Biopsy to Identify Actionable Genomic Alterations.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018Review
- Role of circulating tumor DNA in the management of early-stage lung cancer.Thoracic cancer · 2018Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29174309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.